Since CRC progression and survival are dependent on the functionality of blood vessels that oxygenate tumor tissues and mediate metabolic processes, targeting RGS5 could potentially be a promising therapeutic approach against vascularized tumors like CRC (Anderson et al., 2023). Here, RGS5 is linked to colorectal carcinoma.